Latest Period
Q4 2025
Security Snapshot
Arcturus Therapeutics Holdings Inc. - Common Stock (ARCT) Institutional Ownership
CUSIP: 03969T109
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
114
Shares (Excl. Options)
23,639,766
Price
$6.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- ARCT on Nasdaq
- Shares outstanding
- 28,423,877
- Price per share
- $8.50
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 23,639,766
- Total reported value
- $144,903,298
- % of total 13F portfolios
- 0%
- Share change
- -2,239,936
- Value change
- -$42,289,773
- Number of holders
- 114
- Price from insider filings
- $8.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ARCT - Arcturus Therapeutics Holdings Inc. - Common Stock is tracked under CUSIP 03969T109.
- 114 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 114 to 47 between Q4 2025 and Q1 2026.
- Reported value moved from $144,903,298 to $65,225,494.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 114 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03969T109?
CUSIP 03969T109 identifies ARCT - Arcturus Therapeutics Holdings Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03969T109:
Significant Owners of Arcturus Therapeutics Holdings Inc. - Common Stock (ARCT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 12% | $20,250,983 | 3,303,640 | Federated Hermes, Inc. | 31 Dec 2025 | |||
| ARK Investment Management LLC | 10% | +13% | $25,054,226 | +$2,859,884 | 2,947,556 | +13% | ARK Investment Management LLC | 30 Apr 2026 |
| BlackRock, Inc. | 7.8% | $27,169,573 | 2,104,537 | BlackRock, Inc. | 31 Mar 2025 | |||
| Amova Asset Management Americas, Inc. | 7.2% | +1.4% | $35,898,599 | +$400,871 | 1,947,835 | +1.1% | Amova Asset Management Americas, Inc. | 30 Sep 2025 |
| Sumitomo Mitsui Trust Group, Inc. | 7.2% | +1.4% | $35,898,599 | +$400,871 | 1,947,835 | +1.1% | Sumitomo Mitsui Trust Group, Inc. | 30 Sep 2025 |
| STATE STREET CORP | 4.9% | $17,120,700 | 1,326,158 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Dec 2025, 114 institutional investors reported holding 23,639,766 shares of Arcturus Therapeutics Holdings Inc. - Common Stock (ARCT). This represents 83% of the company’s total 28,423,877 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Arcturus Therapeutics Holdings Inc. - Common Stock (ARCT) together control 75% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 12% | 3,303,640 | -30% | 0.03% | $20,251,313 |
| BlackRock, Inc. | 9.2% | 2,619,684 | +2.1% | 0% | $16,058,662 |
| ARK Investment Management LLC | 9.2% | 2,611,099 | +39% | 0.11% | $16,006,036 |
| VANGUARD GROUP INC | 7.4% | 2,089,641 | +11% | 0% | $12,809,499 |
| Sumitomo Mitsui Trust Group, Inc. | 7.1% | 2,026,588 | +4% | 0.01% | $12,422,984 |
| Amova Asset Management Americas, Inc. | 7.1% | 2,026,588 | +4% | 0.14% | $12,402,719 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 618,134 | +1% | 0% | $3,789,944 |
| STATE STREET CORP | 2% | 564,266 | -46% | 0% | $3,458,951 |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 546,686 | +513% | 0% | $3,351,185 |
| TWO SIGMA ADVISERS, LP | 1.8% | 511,043 | +1227% | 0.01% | $3,132,694 |
| DIMENSIONAL FUND ADVISORS LP | 1.7% | 490,429 | -12% | 0% | $3,006,448 |
| ACADIAN ASSET MANAGEMENT LLC | 1.5% | 427,894 | +81% | 0% | $2,620,000 |
| JANE STREET GROUP, LLC | 1.5% | 422,419 | +210% | 0% | $2,589,428 |
| Empire Life Investments Inc. | 1.5% | 412,402 | -1.2% | 0.14% | $2,528,024 |
| GOLDMAN SACHS GROUP INC | 1.4% | 391,227 | +170% | 0% | $2,398,222 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 304,777 | +666% | 0% | $1,868,283 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1% | 293,050 | -4.1% | 0.01% | $1,796,396 |
| Hennion & Walsh Asset Management, Inc. | 0.85% | 240,303 | +207% | 0.05% | $1,473,057 |
| UBS Group AG | 0.8% | 227,893 | +42% | 0% | $1,396,984 |
| Point72 Asset Management, L.P. | 0.78% | 222,163 | 0% | $1,361,859 | |
| MORGAN STANLEY | 0.75% | 213,392 | -70% | 0% | $1,308,093 |
| JPMORGAN CHASE & CO | 0.73% | 206,169 | +1.3% | 0% | $1,263,817 |
| NORTHERN TRUST CORP | 0.71% | 200,781 | -7.8% | 0% | $1,230,788 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.65% | 183,855 | -12% | 0% | $1,127,031 |
| BNP PARIBAS FINANCIAL MARKETS | 0.52% | 146,767 | 0% | 0% | $899,682 |
Institutional Holders of Arcturus Therapeutics Holdings Inc. - Common Stock (ARCT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 8,453,999 | $65,225,494 | +$7,368,994 | $7.72 | 47 |
| 2025 Q4 | 23,639,766 | $144,903,298 | -$42,289,773 | $6.13 | 114 |
| 2025 Q3 | 25,813,853 | $475,545,761 | +$6,867,024 | $18.43 | 134 |
| 2025 Q2 | 25,723,468 | $335,038,354 | -$6,831,289 | $13.01 | 140 |
| 2025 Q1 | 26,575,062 | $281,454,102 | -$6,198,440 | $10.59 | 141 |
| 2024 Q4 | 26,610,345 | $451,455,958 | +$561,441 | $16.97 | 144 |
| 2024 Q3 | 26,254,849 | $609,261,942 | -$9,219,231 | $23.21 | 163 |
| 2024 Q2 | 26,274,363 | $639,738,709 | -$34,874,203 | $24.35 | 169 |
| 2024 Q1 | 27,205,455 | $918,443,053 | +$63,004,519 | $33.77 | 176 |
| 2023 Q4 | 25,425,877 | $801,644,603 | +$9,906,113 | $31.53 | 165 |
| 2023 Q3 | 25,171,045 | $643,113,548 | +$38,194,974 | $25.55 | 146 |
| 2023 Q2 | 23,633,969 | $677,565,419 | +$11,461,734 | $28.68 | 143 |
| 2023 Q1 | 23,320,944 | $557,885,187 | +$17,248,370 | $23.97 | 124 |
| 2022 Q4 | 22,638,074 | $383,920,663 | +$11,521,684 | $16.96 | 111 |
| 2022 Q3 | 22,166,410 | $328,065,176 | -$1,828,982 | $14.82 | 106 |
| 2022 Q2 | 20,644,930 | $334,480,556 | +$9,251,825 | $15.74 | 116 |
| 2022 Q1 | 21,454,944 | $578,272,039 | +$36,976,142 | $26.96 | 122 |
| 2021 Q4 | 19,955,158 | $736,203,155 | +$29,436,784 | $37.01 | 133 |
| 2021 Q3 | 19,065,552 | $909,015,330 | -$50,289,411 | $47.78 | 150 |
| 2021 Q2 | 20,506,601 | $693,959,237 | +$36,673,317 | $33.84 | 133 |
| 2021 Q1 | 18,787,112 | $775,920,001 | -$48,861,238 | $41.30 | 153 |
| 2020 Q4 | 19,874,000 | $864,074,837 | +$70,349,611 | $43.38 | 131 |
| 2020 Q3 | 18,215,804 | $783,103,294 | +$221,938,988 | $42.90 | 127 |
| 2020 Q2 | 12,949,979 | $605,805,587 | +$388,736,954 | $46.74 | 112 |
| 2020 Q1 | 4,735,510 | $65,692,000 | +$2,316,123 | $13.59 | 53 |
| 2019 Q4 | 4,554,811 | $50,089,000 | -$172,871 | $10.87 | 49 |
| 2019 Q3 | 4,612,453 | $47,342,000 | +$27,908,866 | $10.27 | 39 |
| 2019 Q2 | 1,877,652 | $17,728,000 | +$17,719,999 | $9.44 | 20 |